Baxter To Exit Drug Price Inflation MDL For $30M
Both Baxter and the relator told U.S. District Judge Patti B. Saris, who is overseeing the MDL, that they wished to settle their dispute “to avoid the delay, expense, inconvenience and uncertainty of protracted litigation of these disputed claims.”
Under the terms of the settlement agreement, the U.S. will get $25 million, while $1.6...
Already a subscriber? Click here to login